Release Date: 03/01/2022
Expiration Date: 03/01/2023
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Stephanie T. Weiss, MD PhD
Staff Research Physician
Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health
Moderator & Organizer
Shawn M. Varney, MD, FAACT, FACEP, FACMT
Professor of Emergency Medicine
Medical Director, South Texas Poison Center
University of Texas Health Science Center San Antonio
Has disclosed no relevant financial relationships
Opioid use is commonplace in the United States whether for acute situations, chronic pain, recreational use, or misuse. In addition, the opioid epidemic continues unabated, further leading to morbidity and mortality. Addiction medicine, as well as clinical and forensic medicine, employ opioid testing programs as part of their diagnostic and therapeutic regimens. Clinicians and scientists must understand opioid metabolism and disposition to accurately assess patients’ risk of toxicity relating to various genetic, clinical, and social factors. This webinar will review common urine drug testing technologies and classification of opiates/opioids. Further, the webinar will discuss the chemical relationships between common opiates and semi-synthetic opioids. Finally, it will identify three factors that may complicate urine drug testing interpretation.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives – After attending this program you should be able to:
- Discuss properties of americium relevant to the medical management of an incident involving americium.
- Discuss the indications, mechanism of action, and dosing of DTPA in treating americium exposures.
- Describe a case to reinforce the learner’s understanding.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
Enduring UAN: JA4008163-9999-22-041-H04-P